Ignite Creation Date:
2024-05-06 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03672539
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2018-09-10
Brief Title:
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia AML or High Risk Myelodysplastic Syndrome
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-11-07
Start Date Type:
ACTUAL
Primary Completion Date:
2025-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2018-09-10
First Submit QC Date:
September 13 2018
Study First Post Date:
2018-09-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-30
Last Update Post Date:
2024-05-08
Last Update Post Date Type:
ACTUAL